Updates to the Guidelines for the Prevention and Treatment of Opportunistic Infections in Children with and Exposed to HIV

August 3, 2023: The Panel on Opportunistic Infections in Children with and Exposed to HIV (the Panel) updated the Guidelines for the Prevention and Treatment of Opportunistic Infections in Children with and Exposed to HIV. Highlights from the updated sections are summarized below:  Introduction Cytomegalovirus For a list of recent updates, please see What’s New in the Guidelines. To…

Read More

Updates to the Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV

The Panel on Opportunistic Infections in Adults and Adolescents (the Panel) updated the Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV. Highlights from the updated section are summarized below:  Monkeypox Added a brief statement about monkeypox with a link to information from the Centers for Disease Control and Prevention (CDC). Information…

Read More

FDA Approves First Injectable Treatment for #HIV Pre-Exposure Prevention (PrEP)

On December 10, 2021, the U.S. Food and Drug Administration approved Apretude (cabotegravir extended-release injectable suspension) for use in at-risk adults and adolescents weighing at least 35 kilograms (77 pounds) for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV. Apretude is given first as two initiation injections administered one month apart, and then every…

Read More

Updates to Perinatal HIV Clinical Guidelines

January 5, 2022: The Panel on Treatment of HIV During Pregnancy and Prevention of Perinatal Transmission recently updated several sections of the Recommendations for the Use of Antiretroviral Drugs During Pregnancy and Interventions to Reduce Perinatal HIV Transmission in the United States. The following sections were among those updated: Maternal HIV Testing and Identification of Perinatal…

Read More

Updates to the Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV

This notice updates and corrects an announcement on this subject sent January 20, 2022. The Panel on Antiretroviral Guidelines for Adults and Adolescents (the Panel) updated the following sections of the Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV. Highlights are summarized below: Early (Acute and Recent) HIV Infection…

Read More